Program
brimonidine
Also written as “Brimonidine”, “Brimonidine Tartrate” and “CD07805/47 Gel”.
Its studies are mostly in Glaucoma · Rosacea · Glaucoma, Open-Angle · Conjunctivitis, Allergic · Hyperemia, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 220 open or running | phase 4since Apr 6, 2007 | Sep 12, 2005 | none ahead |
| Galderma Group | 100 open or running | phase 4since Sep 23, 2014 | Jun 12, 2008 | none ahead |
| Bausch Health Companies | 70 open or running | phase 3since Oct 8, 2013 | Oct 8, 2013 | none ahead |
| Eye Therapies | 30 open or running | phase 2since Jan 10, 2011 | Jan 10, 2011 | none ahead |
| Ocugen | 30 open or running | phase 3since Jul 9, 2018 | Oct 10, 2017 | none ahead |
| Alcon | 20 open or running | phase 4since Dec 1, 2008 | May 28, 2003 | none ahead |
| Tarian Pharma | 22 open or running | phase 2since Jan 23, 2025 | Jan 23, 2025 | none ahead |
| Biogen | 10 open or running | phase 4since Oct 1, 2015 | Oct 1, 2015 | none ahead |
| Innovative Medical | 10 open or running | phase 4since Jun 30, 2006 | Jun 30, 2006 | none ahead |
| Teva Pharmaceutical Industries | 10 open or running | phase 3since Oct 31, 2014 | Oct 31, 2014 | none ahead |
Also a collaborator on its studies: ORA and eurotrials-brasil-consultores-cientificos-ltda.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 37 studies since May 28, 2003.
- Mar 12, 2014Phase 2 study in Geographic AtrophyAbbVie · NCT02087085 · 310 enrolled · United States, Australia, France and more
- Sep 23, 2014Phase 4 study in RosaceaGalderma Group · NCT02249065 · 205 enrolled · United States
- Oct 31, 2014Teva Pharmaceutical Industries's first study: phase 3 study in RosaceaNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT02289352 · 462 enrolled · United States
- Oct 1, 2015Biogen's first study: phase 4 study in Multiple Sclerosis, Relapsing-RemittingNew to BiogenBiogen · NCT02568111
- Nov 24, 2015Phase 4 study in RosaceaGalderma Group · NCT02616250 · 190 enrolled · United States, Canada
- Jul 19, 2016Phase 4 study in Chronic Persistent Vascular Facial ErythemaGalderma Group · NCT02856919 · 101 enrolled · Brazil
- Oct 10, 2017Ocugen's first study: phase 2 study in Dry Eye SyndromesNew to OcugenOcugen · NCT03418727 · 84 enrolled · United States
- Jul 9, 2018Phase 3 study in Graft vs Host DiseaseOcugen · NCT03591874 · 59 enrolled · United States
- Dec 20, 2018Phase 3 study in Dry Eye SyndromesOcugen · NCT03785340 · 252 enrolled · United States
- Apr 29, 2022Phase 3 study in Ocular RednessBausch Health Companies · NCT05360784 · 380 enrolled · United States
- Oct 6, 20222 phase 3 studiesBausch Health Companies · NCT05591755, NCT05579730
- Mar 21, 2023Phase 3 study in Conjunctivitis, AllergicBausch Health Companies · NCT05815758 · 512 enrolled · United States
- Jan 23, 2025Tarian Pharma's first study: phase 2 study in EGFR Inhibitor-associated RashNew to Tarian PharmaTarian Pharma · NCT06818058 · 60 planned · France
- Jul 3, 2025Phase 2 study in Chemotherapy Induced Peripheral NeuropathyTarian Pharma · NCT07082764 · 30 planned · France
TargetBeta
“Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexmedetomidinerule | Pfizer | phase 4 | 46 |
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| tizanidinerule | Teva Pharmaceutical Industries | phase 4 | 11 |
| Clonidinerule | pharmafina | phase 4 | 5 |
| lofexidinerule | uswm-llc-dba-us-worldmeds | phase 3 | 15 |
Studies
All 52 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07082764Chemotherapy Induced Peripheral Neuropathy · France | 2 | Not yet recruiting | Tarian Pharma | Sep 30, 2026 | 30 |
| NCT06818058EGFR Inhibitor-associated Rash · France | 2 | Recruiting | Tarian Pharma | Sep 1, 2026 | 60 |
| NCT05815758Conjunctivitis, Allergic · United States | 3 | Completed | Bausch Health Companies | Sep 18, 2023 | 512 |
| NCT05591755Seasonal Allergic Conjunctivitis · United States | 3 | Completed | Bausch Health Companies | Aug 9, 2023 | 229 |
| NCT05579730Conjunctivitis, Allergic · United States | 3 | Completed | Bausch Health Companies | Jul 22, 2023 | 188 |
| NCT05360784Ocular Redness · United States | 3 | Completed | Bausch Health Companies | Nov 23, 2022 | 380 |
| NCT03785340Dry Eye Syndromes · United States | 3 | Completed | Ocugen | Feb 25, 2019 | 252 |
| NCT03591874Graft vs Host Disease · United States | 3 | Terminated | Ocugen | Apr 30, 2020 | 59 |
| NCT03418727Dry Eye Syndromes · United States | 2 | Completed | Ocugen | Mar 29, 2018 | 84 |
| NCT02856919Chronic Persistent Vascular Facial Erythema · Brazil | 4 | Completed | Galderma Group | Feb 8, 2017 | 101 |
| NCT02616250Rosacea · United States, Canada | 4 | Completed | Galderma Group | Sep 2016 | 190 |
| NCT02568111Multiple Sclerosis, Relapsing-Remitting | 4 | Withdrawn | Biogen | Aug 2016 | 0 |
| NCT02289352Rosacea · United States | 3 | Completed | Teva Pharmaceutical Industries | Dec 2014 | 462 |
| NCT02249065Rosacea · United States | 4 | Completed | Galderma Group | Aug 2015 | 205 |
| NCT02087085Geographic Atrophy · United States, Australia, France and more | 2 | Terminated | AbbVie | Mar 30, 2018 | 310 |
| NCT02039765Hyperemia · United States | 1 | Completed | Bausch Health Companies | Mar 2014 | 12 |
| NCT02003534Glaucoma, Open-Angle · China | 4 | Completed | AbbVie | Feb 2013 | 376 |
| NCT01959243Hyperemia · United States | 3 | Completed | Bausch Health Companies | Apr 23, 2014 | 507 |
| NCT01959230Hyperemia · United States | 3 | Completed | Bausch Health Companies | Dec 20, 2013 | 60 |
| NCT01882712Erythema | 3 | Withdrawn | Galderma Group | Sep 2015 | 0 |
| NCT01863953Glaucoma · United States | 2 | Completed | AbbVie | Dec 2013 | 112 |
| NCT01687426Glaucoma · United States | 1 | Completed | Eye Therapies | Dec 2012 | 15 |
| NCT01675609Ocular Redness · United States | 2 | Completed | Eye Therapies | Oct 2012 | 57 |
| NCT01525173Glaucoma · United States | 4 | Completed | AbbVie | Oct 2012 | 137 |
| NCT01355471Rosacea · United States, Canada | 3 | Completed | Galderma Group | Nov 2011 | 293 |
| NCT01355458Rosacea · United States, Canada | 3 | Completed | Galderma Group | Sep 2011 | 260 |
| NCT01318733Rosacea · United States | 3 | Completed | Galderma Group | Jun 2012 | 449 |
| NCT01275105Conjunctivitis, Allergic · United States | 2 | Completed | Eye Therapies | Mar 2011 | 68 |
| NCT01241240Glaucoma, Open-Angle · Colombia, Mexico | 3 | Completed | AbbVie | Sep 2013 | 192 |
| NCT01229462Glaucoma · China | – | Completed | AbbVie | Sep 2011 | 238 |
| NCT01229410Vitrectomy · United States, Czech Republic | 1 | Completed | AbbVie | May 2011 | 24 |
| NCT01217606Glaucoma, Open-Angle · Brazil | 3 | Completed | AbbVie | Sep 2014 | 185 |
| NCT01216943Glaucoma · India | 3 | Completed | AbbVie | Aug 2012 | 126 |
| NCT01174030Rosacea · United States | 2 | Completed | Galderma Group | Dec 2010 | 269 |
| NCT01151904Glaucoma, Angle-Closure · Thailand | 4 | Terminated | AbbVie | Feb 2012 | 17 |
| NCT00989014Rosacea · United States | 2 | Completed | Galderma Group | Nov 2009 | 122 |
| NCT00972374Rhegmatogenous Macula-off Retinal Detachment · United States, India, Israel and more | 2 | Completed | AbbVie | Oct 2010 | 44 |
| NCT00822055Glaucoma, Open-Angle · Canada | 4 | Completed | AbbVie | Nov 2006 | 140 |
| NCT00800540Glaucoma · United States | 4 | Completed | Alcon | Jan 2012 | 35 |
| NCT00697541Erythematous Rosacea · United States | 2 | Completed | Galderma Group | Jun 2008 | 20 |
| NCT00693485Glaucoma, Open-Angle · United States, Israel | 2 | Completed | AbbVie | Jan 2011 | 70 |
| NCT00658619Macular Degeneration · United States, Australia, Germany and more | 2 | Completed | AbbVie | Jun 1, 2010 | 119 |
| NCT00652483Glaucoma · United States | 3 | Completed | AbbVie | Dec 2003 | 433 |
| NCT00651612Glaucoma · United States | 3 | Completed | AbbVie | Jan 2007 | 604 |
| NCT00661479Retinitis Pigmentosa · United States, France, Germany and more | 2 | Completed | AbbVie | Dec 2009 | 21 |
| NCT00457795Glaucoma, Open-Angle · United States | 4 | Completed | AbbVie | Feb 2009 | 15 |
| NCT00348400Glaucoma · United States | 4 | Completed | Innovative Medical | ||
| NCT00332436Ocular Hypertension · United States | 3 | Completed | AbbVie | Nov 2001 | 586 |
| NCT00332384Ocular Hypertension · United States | 3 | Completed | AbbVie | Nov 2001 | 573 |
| NCT00332345Ocular Hypertension · United States | 2 | Completed | AbbVie | Aug 1999 | 73 |
| NCT00168363Glaucoma | 3 | Completed | AbbVie | Aug 2006 | 207 |
| NCT00061529Glaucoma, Open-Angle · United States | 3 | Completed | Alcon | Jul 2004 |
How it is read
Names in the registry
- “Brimonidine”, 4 entries
- “Brimonidine Tartrate”, 4 entries
- “CD07805/47 Gel”, 4 entries
- “CD07805/47”, 3 entries
- “400 µg Brimonidine Tartrate Implant”, 3 entries
Conditions, from the studies’ own filings
- Glaucoma, 10 studies
- Rosacea, 9 studies
- Glaucoma, Open-Angle, 8 studies
- Conjunctivitis, Allergic, 4 studies
- Hyperemia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.